Does the EU Pharmaceutical Sector Inquiry Provide Proof of the Need for a Centralised Patent Court?
This article was originally published in SRA
Executive Summary
Generic drug companies hoping to have cases heard against “weak patents” in the UK courts may be well advised to steer clear of Lord Justice Robin Jacob. A judge in the Court of Appeal, and one of the UK’s most experienced patent judges, Lord Justice Jacob recently suggested that the European Commission’s inquiry into competition in the pharmaceutical sector was simply “a waste of time”.